Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn’s Disease Patients

Table 1

Characteristics of the studies included in the meta-analysis.

Study (ref)	Drug	N drug/placebo	Inclusion	Outcome	Population characteristic	Time (wks)
Sandborn et al., PRECISE 1 [22]	Certolizumab	97/85	No primary nonresponders	Response	Subgroup	6
Sandborn et al., GAIN [23]	Adalimumab	159/166	No primary nonresponders	Remission/response	Whole	4
Sandborn et al. [24]	Ustekinumab	394/132	Primary/secondary nonresponse, adverse events	Remission/response (3 different doses)	Whole	8
Sandborn et al. [21]	Ustekinumab	25/27	Previous exposure	Response (2 different doses)	Subgroup	8
Sands, GEMINI 3 (25)	Vedolizumab	158/157	Primary/secondary nonresponse, adverse events	Remission/response	Whole	10
Sandborn et al. [26]	Vedolizumab	105/70	Primary/secondary nonresponse, adverse events	Remission/response	Subgroup	6
Sands et al. [27]	Natalizumab	52/27	Secondary nonresponders	Remission	Whole	10
Sandborn et al. [28]	Natalizumab	291/69	Not specified	Remission/response	Subgroup	10